MaxCyte beats Q3 EPS and revenue estimates, issues FY revenue guidance above consensus (MXCT:NASDAQ)
· seekingalpha.com
MaxCyte Q3 revenue rises 49.3% to $10.2 million; 2026 revenue guidance rises to at least $34.5 million, with full-year growth projected.
Search field
Entering text into the input field will update the search result below